Using memantine to prevent Alzheimer's disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the feasibility of using memantine hydrochloride as a preventive treatment for Alzheimer's Disease (AD) in individuals at risk. It targets participants aged 50-65 who are APOE4 positive and have a family history of AD. The study will enroll up to 128 subjects, with 32 randomized to receive either memantine or a placebo over a treatment period of 101 weeks. Various cognitive and safety assessments will be conducted to determine the effectiveness and safety of the intervention.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Be between the age of 50 and 65 years at time of informed consent.
2. Have a positive family history for dementia (minimum of 1 first degree relative).
3. Previously known or documented heterozygote or homozygote ApoE ε4 allele.
4. Be able to read and write and must have adequate hearing and visual acuity to complete the psychometric tests.
5. Be otherwise healthy for their age group or medically stable with or without medication on the basis of physical examination, medical history, vital signs, and 12-lead ECG performed at screening or at baseline.
6. Have Montreal Cognitive Assessment (MOCA) score of 27 or above.
7. Have a creatinine clearance (CrCl), estimated using the Cockcroft-Gault formula, greater or equal to 30 mL/minute.

Exclusion Criteria:

1. A current clinical condition or requires a medication that raises the pH of their urine.
2. Severe renal or hepatic impairment.
3. Any other abnormality that could cause a possible cognitive deficit (including, but not limited to, vascular encephalopathy or large strokes).
4. Contraindications for MRI (e.g., prostheses, implants, claustrophobia, pacemaker) or PET imaging.
5. Neurodegenerative disorder known to cause neurocognitive decline
6. Relevant history of or current neurological disease other than preclinical AD, which may make interpretation of possible new neurological signs or symptoms difficult.
7. Clinically significant and active pulmonary, gastrointestinal, renal, hepatic, endocrine, or cardiovascular system disease
8. Ongoing cancer treatment
9. Clinically significant and active psychiatric disorder
10. Use of an investigational medical device within 3 months before the planned start of study.
11. Current participation in an interventional study with an investigational drug component.
12. Major surgery (e.g., requiring general anesthesia) within 8 weeks before screening, or will not have fully recovered from surgery, or has major surgery planned during the time the subject is expected to participate in the study.
13. Requires treatment with an AChE inhibitor or any of the following: acetazolamide, methazolamide, amantadine, ketamine, dextromethorphan.

Where it's running

• University of Virginia
  Charlottesville, Virginia, United States Recruiting

Study contacts

• Principal investigator: Carol Manning, PhD — Professor of Neurology
• Study coordinator: Amy Fansler
• Email: acf7h@virginia.edu
• Phone: 434-243-1760

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Blood biomarker cohort for memory disorders in older adults

  This observational cohort will collect blood samples and brain imaging data from adults 50+ with memory disorders and a small group of healthy young adults to help find biomarkers.

  Recruiting Yonsei University · Seoul, Seodamun-gu · NCT07880275

• Tau changes after hip or knee replacement surgery

  Researchers will see if brain tau changes after hip or knee surgery and whether these changes relate to inflammation and thinking abilities.

  Recruiting Uppsala University Hospital · Uppsala · NCT07871487

• Low-Dose Whole-Brain Radiation Therapy With HeLaXON 1X in Mild Alzheimer's Dementia

  This study will test whether a low-dose brain radiation treatment using HeLaXON helps people with mild Alzheimer's dementia improve or stabilize thinking and daily function.

  Recruiting ReadyCure Inc. · Cheonan, Chungcheongnam-do · NCT07863011

• Cervical lymphatic surgery to see if it helps people with mild Alzheimer’s

  We’re testing a surgical approach in people with mild Alzheimer’s to see if creating alternative neck lymph drainage routes can affect brain biomarkers and daily function.

  Recruiting at 2 sites Maliszewski Daniel · Gdansk and 1 other locations · NCT07857759

• Transcranial random noise stimulation for behavioral and psychological symptoms in Alzheimer's disease

  This trial tests whether high-frequency transcranial random noise stimulation can help people with early Alzheimer's disease who have BPSD, compared to a sham treatment.

  Recruiting Anhui Medical University · Hefei, Anhui · NCT07827196

• Testing LY4405094 in healthy people and people with Alzheimer’s disease

  This study tests LY4405094 to see if it is safe and how it behaves in the body, including how it reaches the brain fluid in healthy participants and how it affects a brain protein in people with Alzheimer's disease.

  Recruiting Phase 1 Eli Lilly and Company · Anaheim, California and 17 other locations · NCT07787182

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.